New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - mepolizumab 100 mg/ml - solution for injection - 100 mg/ml - active: mepolizumab 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate disodium edetate polysorbate 80 sucrose water for injection - nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (2.5lfu); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu; tetanus toxoid 20 [iu] (5lfu) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (2.5lfu) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu tetanus toxoid 20 [iu] (5lfu) excipient: aluminium medium 199 sodium chloride water for injection - boostrix®-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. boostrix®-ipv is not intended for primary immunisation.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage);  ; ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - powder for injection - active: potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage)   ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - the treatment of infections caused by susceptible strains of organisms in the conditions listed below: - septicaemia (including bacteraemia) - lower respiratory tract infections - bone and joint infections - skin and skin structure infections - urinary tract infections - gynaecological infections - surgical prophylaxis appropriate culture and susceptibility tests should be performed in order to isolate and identify organisms causing infection and to determine their susceptibility to timentin. susceptibility to timentin will vary with geography and time and local succeptibility data should be consulted where available. in certain infections, when the causative organisms are unknown, timentin may be administered in conjunction with an aminoglycoside as initial therapy. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal hysterectomy, abdominal surgery, and colorectal surgery when there is a significant risk of postoperative infection or where occurrence of postoperative infection is considered to be especially serious.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 10 mg/ml - solution for injection - 200mg/20ml - active: zidovudine 10 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - retrovir iv for infusion is indicated for the short-term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immune deficiency syndrome (aids), who are unable to take retrovir oral formulations.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss);   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss)   excipient: norflurane - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - aciclovir 200mg; aciclovir 200mg - dispersible tablet - 200 mg - active: aciclovir 200mg excipient: aluminium magnesium silicate hypromellose indigo carmine macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate active: aciclovir 200mg excipient: aluminium magnesium silicate hypromellose macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate titanium dioxide - zovirax dispersible tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. zovirax dispersible tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. zovirax dispersible tablets are indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - aciclovir 400mg; aciclovir 400mg - dispersible tablet - 400 mg - active: aciclovir 400mg excipient: aluminium magnesium silicate hypromellose iron oxide red macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate active: aciclovir 400mg excipient: aluminium magnesium silicate hypromellose macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate titanium dioxide - zovirax dispersible tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. zovirax dispersible tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. zovirax dispersible tablets are indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - aciclovir 800mg - dispersible tablet - 800 mg - active: aciclovir 800mg excipient: aluminium magnesium silicate hypromellose macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate titanium dioxide - zovirax dispersible tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. zovirax dispersible tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. zovirax dispersible tablets are indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamivudine 150mg;   - film coated tablet - 150 mg - active: lamivudine 150mg   excipient: magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g sodium starch glycolate - 3tc in combination with other anti-retroviral agents is indicated for the treatment of hiv infected adults and children.